skip to Main Content

Phase I/II Advanced HER2+ Breast Cancer Study

Biotech with a promising compound but a highly complex protocol design and a scarcity of comparator arm naïve patients in the U.S.

A biotech with a promising compound but a highly complex protocol design was facing a scarcity of comparator arm naïve patients in the U.S. The trial had been ongoing for 6 months at 7 sites in the U.S.

See how Canada recruited 55% of the patients with only 33% of the sites.

Complete This Form
To Download

  • This field is for validation purposes and should be left unchanged.
Back To Top
×Close search
Search